scispace - formally typeset
Search or ask a question
Topic

Shigella dysenteriae

About: Shigella dysenteriae is a research topic. Over the lifetime, 1337 publications have been published within this topic receiving 36821 citations.


Papers
More filters
Journal Article
TL;DR: Shigellosis, which continues to have an important global impact, cannot be adequately controlled with the existing prevention and treatment measures, and innovative strategies, including development of vaccines against the most common serotypes, could provide substantial benefits.
Abstract: Few studies provide data on the global morbidity and mortality caused by infection with Shigella spp.; such estimates are needed, however, to plan strategies of prevention and treatment. Here we report the results of a review of the literature published between 1966 and 1997 on Shigella infection. The data obtained permit calculation of the number of cases of Shigella infection and the associated mortality occurring worldwide each year, by age, and (as a proxy for disease severity) by clinical category, i.e. mild cases remaining at home, moderate cases requiring outpatient care, and severe cases demanding hospitalization. A sensitivity analysis was performed to estimate the high and low range of morbid and fatal cases in each category. Finally, the frequency distribution of Shigella infection, by serogroup and serotype and by region of the world, was determined. The annual number of Shigella episodes throughout the world was estimated to be 164.7 million, of which 163.2 million were in developing countries (with 1.1 million deaths) and 1.5 million in industrialized countries. A total of 69% of all episodes and 61% of all deaths attributable to shigellosis involved children under 5 years of age. The median percentages of isolates of S. flexneri, S. sonnei, S. boydii, and S. dysenteriae were, respectively, 60%, 15%, 6%, and 6% (30% of S. dysenteriae cases were type 1) in developing countries; and 16%, 77%, 2%, and 1% in industrialized countries. In developing countries, the predominant serotype of S. flexneri is 2a, followed by 1b, 3a, 4a, and 6. In industrialized countries, most isolates are S. flexneri 2a or other unspecified type 2 strains. Shigellosis, which continues to have an important global impact, cannot be adequately controlled with the existing prevention and treatment measures. Innovative strategies, including development of vaccines against the most common serotypes, could provide substantial benefits.

1,262 citations

Journal ArticleDOI
TL;DR: Findings indicate that E. coli produces two genetically related but antigenically distinct cytotoxins with similar biologic activities which are proposed to name Shiga-like toxins I and II.
Abstract: Escherichia coli O157:H7 strain 933 contains two distinct toxin-converting phages (933J and 933W). The biologic activities and antigenic relationship between the toxins produced by 933J and 933W lysogens of E. coli K-12, as well as the homology of the genes that encode the two toxins, were examined in this study. The 933J and 933W toxins, like Shiga toxin produced by Shigella dysenteriae type 1, were cytotoxic for the same cell lines, caused paralysis and death in mice, and caused fluid accumulation in rabbit ileal segments. The cytotoxic activity of 933J toxin for HeLa cells was neutralized by anti-Shiga toxin, whereas the activity of 933W toxin was not neutralized by this antiserum. In contrast, an antiserum prepared against E. coli K-12(933W) neutralized 933W toxin but not 933J toxin or Shiga toxin. For E. coli 933, most of the cell-associated cytotoxin was neutralized by anti-Shiga toxin, whereas most of the extracellular cytotoxin was neutralized by anti-933W toxin. However, a mixture of these antisera indicated the presence of both toxins in cell lysates and culture supernatants. Among 50 elevated cytotoxin-producing strains of E. coli, we identified 11 strains isolated from cases of diarrhea, hemorrhagic colitis, or hemolytic uremic syndrome that produced cell-associated cytotoxins which were neutralized by the 933W antitoxin. Southern hybridization studies showed that the cloned toxin structural genes from phage 933J hybridized with DNA from phage 933W under conditions estimated to allow no more than 26% base-pair mismatch. These findings indicate that E. coli produces two genetically related but antigenically distinct cytotoxins with similar biologic activities which we propose to name Shiga-like toxins I and II. Strains of E. coli that produce elevated levels of Shiga-like toxin I or Shiga-like toxin II, or both, have been associated with the clinical syndromes of diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome. Images

584 citations

Journal ArticleDOI
TL;DR: There is little doubt that inhibitors of microbial lectins will in the near future join the arsenal of drugs for therapy of infectious diseases, and polyvalent saccharides are also powerful inhibitors of bacterial adhesion in vitro.

495 citations

Journal ArticleDOI
TL;DR: Strains of Escherichia coli previously implicated or proven to be causes of diarrhea were examined for production of a toxin similar to that of Shigella dysenteriae type 1 (Shiga), suggesting that Shiga-like toxin may be another heretofore undiscovered factor in the pathogenesis of diarrhea caused by some E. coli strains.
Abstract: Strains of Escherichia coli previously implicated or proven to be causes of diarrhea were examined for production of a toxin similar to that of Shigella dysenteriae type 1 (Shiga). Organisms grown in an iron-depleted broth were lysed by pressure disruption followed by ultracentrifugation. Saline-dialyzed extracts were tested for cytotoxic effects on HeLa cells that were neutralizable with antiserum to Shiga toxin. Among the 13 E. coli strains so analyzed, 11 made a Shiga-like cytotoxin in levels ranging from trace (two avirulent isolates) to amounts equivalent to S. dysenteriae type 1 (two noninvasive strains that did not make E. coli heat-labile or -stable enterotoxins but were isolated from infants with diarrhea). As with extracts of Shiga toxin, lysates of these E. coli strains that produced high levels of Shiga-like toxin were enterotoxic for rabbits, paralytic and lethal for mice, and inhibited protein synthesis in HeLa cells. Thus, these data suggest that Shiga-like toxin may be another heretofore undiscovered factor in the pathogenesis of diarrhea caused by some E. coli strains.

443 citations

Book ChapterDOI
TL;DR: The definitive description of this organism was provided by Kiyoshi Shiga following an extensive dysentery epidemic in Japan in 1896 (Shiga 1898), and in 1900 Flexner concluded that shigellosis was due to a “toxic agent rather than to an infection per se”.
Abstract: Dysentery was well known and clearly described in many ancient texts and histories. The first step towards the description of the genus Shigella, however, was the identification of Entamoeba histolytica by Losch in 1875 and the separation of amebic from all other forms of dysentery (Losch, 1875). With this discovery, attention could be focused on the etiology of epidemic dysentery, and a partial description of the prototype Shigella sp., Shigella dysenteriae type 1, was published by Chantemesse and Widal in 1888. The definitive description of this organism was provided by Kiyoshi Shiga following an extensive dysentery epidemic in Japan in 1896 (Shiga 1898). It did not take long to determine that there was a potent toxic activity in this organism, and in 1900 Flexner reported that either living or killed cultures of Shiga’s bacillus injected into the peritoneal cavity of animals caused fever and diarrhea. Flexner concluded that shigellosis was due to a “toxic agent rather than to an infection per se”; however, the Observed effects were Probably due to endotoxin. The presence of a lethal toxin in extracts of heat-killed bacteria was shown independently by Neisser and Shiga (1903) and by Conradi (1903). Conradi (1903) also described the limb paralysis following parenteral inoculation of Shigella extracts in rabbits, characteristic of the so-called Shiga neurotoxin.

418 citations


Network Information
Related Topics (5)
Virulence
35.9K papers, 1.3M citations
80% related
Escherichia coli
59K papers, 2M citations
77% related
Drug resistance
28.4K papers, 1.1M citations
77% related
Antigen
170.2K papers, 6.9M citations
77% related
Immunity
24K papers, 1M citations
76% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20241
202327
202250
202121
202020
201924